Dr. Chughtai’s research portfolio includes over 300 peer-reviewed articles, chapters in urologic texts, and contributions to four textbooks, demonstrating a significant commitment to advancing urological science. He has played a pivotal role in numerous clinical trials, translational research projects, and outcomes research studies, supported by the National Institutes of Health and various industry sponsors.
Below is the list of active clinical trials that Dr. Chughtai oversees. For more information on his current research studies, you can schedule an appointment with Dr. Chughtai, or contact his research team at 516-760-3890.
- A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift System in Subjects with Symptomatic Benign Prostatic Hyperplasia (BPH)
The iTind is a minimally invasive temporary device designed to relieve LUTS secondary to BPH. This study is designed to compare the minimally invasive iTind device to the UroLift System. - A prospective, randomized, controlled, blinded study to assess the Safety and Effectiveness of the Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients.
The Butterfly Prostatic Retraction Device is a minimally invasive permanent implant designed to relieve LUTS secondary to BPH. This study is designed to assess the effectiveness of the Butterfly device in reducing the symptoms associated with BPH. - APEX: A prospective multi-site registry of real-world experience with the OPtilume BPH Catheter SystEm for treatment of men eXperiencing symptomatic BPH.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy designed to relieve LUTS secondary to BPH. This study is designed to verify the continued safety and effectiveness for the Optilume BPH Catheter System.
For a list of Dr. Chughtai’s publications, click here.